Structure of AZD9833, a selective oestrogen receptor degrader (SERD)

oral selective ER degrader and antagonist

in Ph. IIb studies for ER+ breast cancer

from ligand-based design and opt.

J. Med. Chem., Sep. 29, 2020

AstraZeneca, Cambridge, UK / Waltham, MA

AZD9833 is a potent, orally available selective estrogen receptor degrader (SERD) and antagonist in development for breast cancer. The only approved SERD is the widely used fulvestrant, which is given…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.